Oncolytics Biotech (TSE:ONC) had its target price cut by analysts at Royal Bank of Canada from C$15.00 to C$14.00 in a research report issued to clients and investors on Monday. The brokerage currently has an “outperform” rating on the stock. Royal Bank of Canada’s target price indicates a potential upside of 73.70% from the stock’s previous close.
Separately, Paradigm Capital increased their price objective on Oncolytics Biotech from C$2.50 to C$3.25 and gave the company a “speculative buy” rating in a research note on Monday, February 26th.
Oncolytics Biotech traded down C$0.09, reaching C$8.06, during trading hours on Monday, Marketbeat reports. 11,239 shares of the stock were exchanged, compared to its average volume of 34,607. Oncolytics Biotech has a twelve month low of C$3.99 and a twelve month high of C$10.65.
Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Friday, March 9th. The company reported C($0.03) earnings per share (EPS) for the quarter.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.